Geneva, Aug. 5 -- International Clinical Trials Registry received information related to the study (ACTRN12625000765426) titled 'OPAL study - User Experience with Tubeless Automated Insulin Delivery System (Omnipod 5)' on July 18.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Masking: Open (masking not used)
Assignment: Parallel
Type of endpoint: Efficacy
Primary Sponsor: Child and Adolescent Health Service (CAHS)
Condition:
Type 1 Diabetes
Type 1 Diabetes
Metabolic and Endocrine - Diabetes
Intervention:
The intervention arm will receive an Omnipod 5 device for use during the 6-month study period. The Omnipod 5 consists of a pod unit with a reservoir of insulin inside, that has...